Darnestown, MD, United States of America

Kevin P Baker

This inventor holds 92 USPTO granted patents and 5 published patent applications, plus 2 CIPO patents and 6 EPO patents, primarily in Antibody Therapeutics (CPC class C12N1-512). Top assignees: Genentech, Inc., Human Genome Sciences, Inc., Genetech, Inc.. Active years: 2000-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kevin P Baker. Retrieved from https://idiyas.com/inventor/kevin-p-baker

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 92 (Patent Applications = 5)

% Patents Active = 79.3

CIPO Patents = 2 (Patent Applications = 10)

EPO Patents = 6 (Patent Applications = 6)

Average Co-Inventor Count = 5.9

ph-index = 12

Forward Citations = 392(Granted Patents)

Forward Citations (Not Self Cited) = 389(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Rockville, MD (US) (2001)
San Mateo, CA (US) (2000 - 2003)
Millbrae, CA (US) (2000 - 2006)
Darnestown, CA (US) (2006)
Damestown, MD (US) (2006 - 2010)
Darnestown, MD (US) (2003 - 2013)
Burlingame, CA (US) (2008 - 2023)

Company Filing History:

Human Genome Sciences, Inc.

Five Prime Therapeutics, Inc.

patents

5. 1 out of 95

Glaxosmithkline Intellectual Property (No.2) Limited

patents

where one patent can have more than one assignee

Years Active: 2000-2023

Loading Chart...

Areas of Expertise:

Anti-CSF1R Antibody

Anti-CD40 Antibody

Mesothelioma Treatment

FGFR1 ECD

B Cell Proliferation

Tumor Necrosis Factor

Secreted Polypeptides

Transmembrane Polypeptides

GMAD Binding

TR18 Polypeptides

PRO Antibodies

Polypeptide Nucleic Acids

92 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11559583 - Anti-CSF1R antibody and agonistic anti-CD40 antibody combination therapy for cancer (2023-01-24),

2. 9775881 - Methods of treating mesothelioma by administration of compounds comprising FGFR1 ECD (2017-10-03),

3. 8518389 - Methods of inhibiting proliferation or immunoglobulin production of B cells using human tumor necrosis factor receptor TR-17 polypeptides (2013-08-27),

4. 7777007 - PRO9907 antibodies (2010-08-17),

5. 7718770 - PRO1305-polypeptides (2010-05-18),

6. 7700736 - PRO350 antibodies (2010-04-20),

7. 7696319 - PRO1772 antibodies (2010-04-13),

8. 7563867 - PRO4356 polypeptides (2009-07-21),

9. 7550569 - Antibodies that specifically bind to GMAD (2009-06-23),

10. 7504480 - PRO10275 polypeptides (2009-03-17),

11. 7498027 - Methods of treatment using human tumor necrosis factor receptor TR17 antibodies (2009-03-03),

12. 7491797 - PRO6308 polypeptide (2009-02-17),

13. 7479545 - PRO6001 antibodies (2009-01-20),

14. 7470771 - Secreted and transmembrane polypeptides and nucleic acids encoding the same (2008-12-30),

15. 7456261 - PRO9830 antibodies (2008-11-25),

Title: The Innovative Journey of Kevin P Baker

Introduction: Kevin P Baker, a talented inventor based in Darnestown, MD (US), has made significant contributions to the field of technology through his creative and groundbreaking inventions.

Latest Patents: Kevin P Baker holds several patents in various technological domains, showcasing his versatility and ingenuity in the innovation landscape.

Career Highlights: With a career spanning over two decades, Kevin P Baker has consistently pushed the boundaries of technology with his inventive solutions. His keen eye for detail and problem-solving skills have led to the development of cutting-edge products that have revolutionized the industry.

Collaborations: Throughout his career, Kevin P Baker has collaborated with leading tech companies and research institutions to bring his ideas to life. His ability to work in multidisciplinary teams has resulted in successful partnerships and groundbreaking innovations.

Conclusion: Kevin P Baker's passion for innovation and his relentless pursuit of excellence have established him as a prominent figure in the world of inventors. His dedication to pushing the limits of technology continues to inspire future generations of inventors and innovators.

Profile summary based on public USPTO records.